Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin(ogen)*

Interactions of the developmentally regulated chondroitin sulfate proteoglycan NG2 with human plasminogen and kringle domain-containing plasminogen fragments have been analyzed by solid-phase immunoassays and by surface plasmon resonance. In immunoassays, the core protein of NG2 binds specifically and saturably to plasminogen, which consists of five kringle domains and a serine protease domain, and to angiostatin, which contains plasminogen kringle domains 1–3. Apparent dissociation constants for these interactions range from 12 to 75 nm. Additional evidence for NG2 interaction with kringle domains comes from its binding to plasminogen kringle domain 4 and to miniplasminogen (kringle domain 5 plus the protease domain) with apparent dissociation constants in the 18–71 nm range. Inhibition of plasminogen and angiostatin binding to NG2 by 6-aminohexanoic acid suggests that lysine binding sites are involved in kringle interaction with NG2. The interaction of NG2 with plasminogen and angiostatin has very interesting functional consequences. 1) Soluble NG2 significantly enhances the activation of plasminogen by urokinase type plasminogen activator. 2) The antagonistic effect of angiostatin on endothelial cell proliferation is inhibited by soluble NG2. Both of these effects of NG2 should make the proteoglycan a positive regulator of the cell migration and proliferation required for angiogenesis.

[1]  T. L. Moser,et al.  The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. , 1993, The Journal of biological chemistry.

[2]  K. Hirschi,et al.  PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.

[3]  J. Folkman Clinical Applications of Research on Angiogenesis , 1995 .

[4]  W. Stallcup,et al.  Interaction of the NG2 proteoglycan with the actin cytoskeleton , 1996, Journal of cellular biochemistry.

[5]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[6]  P. Dell’Era,et al.  Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Nishiyama,et al.  Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. , 1993, Molecular biology of the cell.

[8]  H. Chapman,et al.  Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.

[9]  W. Stallcup,et al.  Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen , 1990, The Journal of cell biology.

[10]  T Ochiya,et al.  PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. , 1999, Journal of cell science.

[11]  M. Kramer,et al.  Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. , 1992, Experimental cell research.

[12]  D. Sims,et al.  The pericyte--a review. , 1986, Tissue & cell.

[13]  K. Hirschi,et al.  Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. , 1999, Circulation research.

[14]  P. Lerch,et al.  Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. , 1980, European journal of biochemistry.

[15]  D. Rifkin,et al.  Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.

[16]  C. Heldin,et al.  Co‐localization of NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells in the developing rat brain , 1996, Journal of neuroscience research.

[17]  T. L. Moser,et al.  Binding of human plasminogen to basement-membrane (type IV) collagen. , 1992, The Biochemical journal.

[18]  P. D’Amore,et al.  Heparin and Growth Control of Vascular Cells a , 1989, Annals of the New York Academy of Sciences.

[19]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[20]  J. Félez Plasminogen binding to cell surfaces , 1998 .

[21]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[22]  S. Strickland,et al.  Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm , 1976, Cell.

[23]  W. Stallcup,et al.  Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. , 1995, Experimental cell research.

[24]  H. Kobayashi,et al.  Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. , 1994, Cancer research.

[25]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[26]  M. Llinás,et al.  Ligand specificity of human plasminogen kringle 4. , 1991, Biochemistry.

[27]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[28]  R. Highsmith Isolation and properties of a plasminogen activator derived from canine vascular tissue. , 1981, The Journal of biological chemistry.

[29]  I. Herman,et al.  Pericyte growth and contractile phenotype: Modulation by endothelial‐synthesized matrix and comparison with aortic smooth muscle , 1993, Journal of cellular physiology.

[30]  N. Bouck,et al.  Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.

[31]  B. Wiman,et al.  Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. , 1975, European journal of biochemistry.

[32]  S Ferrone,et al.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.

[33]  A. Nishiyama,et al.  Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. , 1995, Molecular biology of the cell.

[34]  D. Marti,et al.  Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω‐aminocarboxylic acids , 1994 .

[35]  D. Rifkin Cross-talk among proteases and matrix in the control of growth factor action* , 1997 .

[36]  J. Folkman,et al.  Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.

[37]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[38]  W. Stallcup,et al.  High-affinity Binding of Basic Fibroblast Growth Factor and Platelet-derived Growth Factor-AA to the Core Protein of the NG2 Proteoglycan* , 1999, The Journal of Biological Chemistry.

[39]  K. Larsson,et al.  Molecular cloning and characterization of a full‐length cDNA clone for human plasminogen , 1987, FEBS letters.

[40]  W. Stallcup,et al.  Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells , 1998, Journal of cellular physiology.

[41]  L. Lim,et al.  Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas , 1999, Nature Cell Biology.

[42]  M. Schrappe,et al.  Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.

[43]  W. Stallcup,et al.  NG2 proteoglycan and the actin-binding protein fascin define separate populations of actin-containing filopodia and lamellipodia during cell spreading and migration. , 1996, Molecular biology of the cell.

[44]  D. Sane,et al.  Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration In vitro. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[45]  M. O. Dayhoff,et al.  Atlas of protein sequence and structure , 1965 .

[46]  E. Pasquale,et al.  The multi‐PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane‐spanning proteoglycan NG2 , 2000, Journal of cellular biochemistry.

[47]  P. Wesseling,et al.  Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.

[48]  F. Ruggiero,et al.  The Membrane-spanning Proteoglycan NG2 Binds to Collagens V and VI through the Central Nonglobular Domain of Its Core Protein* , 1997, The Journal of Biological Chemistry.

[49]  K. Constantine,et al.  Ligand interactions with the kringle 5 domain of plasminogen. A study by 1H NMR spectroscopy. , 1990, The Journal of biological chemistry.

[50]  D. Barritt,et al.  Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. , 1999, Molecular biology of the cell.

[51]  P A D'Amore,et al.  Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells , 1987, The Journal of cell biology.

[52]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[53]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[54]  A. Nishiyama,et al.  A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. , 1997, Experimental cell research.

[55]  P. Lindahl,et al.  Not all myofibroblasts are alike: revisiting the role of PDGF‐A and PDGF‐B using PDGF‐targeted mice , 1998, Current opinion in nephrology and hypertension.

[56]  R. Timpl,et al.  Binding of the NG2 Proteoglycan to Type VI Collagen and Other Extracellular Matrix Molecules* , 1996, The Journal of Biological Chemistry.

[57]  J. Prince,et al.  The primary structure of NG2, a novel membrane-spanning proteoglycan , 1991, The Journal of cell biology.

[58]  Y. Lu,et al.  The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. , 1999, Biochemical and biophysical research communications.

[59]  D. Walz,et al.  Thrombospondin interaction with plasminogen. Evidence for binding to a specific region of the kringle structure of plasminogen , 1989 .

[60]  M. Llinás,et al.  Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  A. Pearlman,et al.  Chondroitin sulfate proteoglycans in the developing cerebral cortex: The distribution of neurocan distinguishes forming afferent and efferent axonal pathways , 1995, The Journal of comparative neurology.

[62]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[63]  Itzhak D. Goldberg,et al.  Regulation of Angiogenesis , 1996, Experientia Supplementum.

[64]  J. Hoover-Plow,et al.  The cell biology of the plasminogen system , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[65]  S. Pizzo,et al.  Regulation of plasminogen activation by components of the extracellular matrix. , 1990, Biochemistry.

[66]  R. Silverstein,et al.  Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. , 1985, The Journal of biological chemistry.

[67]  R Pasqualini,et al.  NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.

[68]  J. Zeuthen,et al.  Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. , 1985, The Journal of biological chemistry.

[69]  P. Wesseling,et al.  AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS , 1996, The Journal of pathology.

[70]  G. Markus Conformational changes in plasminogen, their effect on activation, and the agents that modulate activation rates — a review , 1996 .